Klaus Klarskov

Prof. Klaus Klarskov


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2005 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
TMTakako Miyamae
Takako Miyamae
DMDavid E Malehorn
David E Malehorn
BLBonnie Lemster
Bonnie Lemster
MMMasaaki Mori
Masaaki Mori
TITomoyuki Imagawa
Tomoyuki Imagawa
RHRaphael Hirsch
Raphael Hirsch
Systemic-onset juvenile idiopathic arthritis (SJIA) is a disease of unknown etiology with an unpredictable response to treatment. We examined two groups of patients to determine whether there are serum protein profiles reflective of active disease and predictive of response to therapy. The first group (n = 8) responded to conventional therapy. The second group (n = 15) responded to an experimental antibody to the IL-6 receptor (MRA). Paired sera from each patient were analyzed before and after treatment, using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). Despite the small number of patients, highly significant and consistent differences were observed before and after response to therapy in all patients. Of 282 spectral peaks identified, 23 had mean signal intensities significantly different (P < 0.001) before treatment and after response to treatment. The majority of these differences were observed regardless of whether patients responded to conventional therapy or to MRA. These peaks represent potential biomarkers of active disease. One such peak was identified as serum amyloid A, a known acute-phase reactant in SJIA, validating the SELDI-TOF MS platform as a useful technology in this context. Finally, profiles from serum samples obtained at the time of active disease were compared between the two patient groups. Nine peaks had mean signal intensities significantly different (P < 0.001) between active disease in patients who responded to conventional therapy and in patients who failed to respond, suggesting a possible profile predictive of response. Collectively, these data demonstrate the presence of serum proteomic profiles in SJIA that are reflective of active disease and suggest the feasibility of using the SELDI-TOF MS platform used as a tool for proteomic profiling and discovery of novel biomarkers in autoimmune diseases.

1 September 2019 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
GKGrace Ahuié Kouakou
Grace Ahuié Kouakou
HGHugo Gagnon
Hugo Gagnon
Vincent LacasseVincent Lacasse
Vincent Lacasse
JWJ. Richard Wagner
J. Richard Wagner
SNStephen Naylor
Stephen Naylor
Klaus KlarskovKlaus Klarskov
Klaus Klarskov

26 October 2015 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
AFAurore Flandrin
Aurore Flandrin
SASebastien Allouche
Sebastien Allouche
YRYoann Rolland
Yoann Rolland
FMFrançois‐Olivier McDuff
François‐Olivier McDuff
JWJ. Richard Wagner
J. Richard Wagner
Klaus KlarskovKlaus Klarskov
Klaus Klarskov

6 June 2007 in International Journal of Mass Spectrometry
Verified
Journal Article
Closed access
RMRuth Menque Methogo
Ruth Menque Methogo
PDPatrick DANSETTE
Patrick DANSETTE
Klaus KlarskovKlaus Klarskov
Klaus Klarskov

15 December 2004 in Proteomics
Verified
Journal Article
Closed access
PDF file
GDGeneviève Dufresne‐Martin
Geneviève Dufresne‐Martin
JLJean‐François Lemay
Jean‐François Lemay
PLPierre Lavigne
Pierre Lavigne
Klaus KlarskovKlaus Klarskov
Klaus Klarskov

2 March 2020 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
GAGrace Kouakou Ahuie
Grace Kouakou Ahuie
HGHugo Gagnon
Hugo Gagnon
PPPaul E. Pace
Paul E. Pace
APAlexander V. Peskin
Alexander V. Peskin
RWRichard J. Wagner
Richard J. Wagner
Klaus KlarskovKlaus Klarskov
Klaus Klarskov